Close Menu

William Blair

Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.

The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.

The immune sequencing firm announced preliminary full-year 2019 revenues in the range of $84 million to $85 million, an increase of approximately 52 percent.

Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.

More than a third of NGS users plan to purchase a new sequencing system within a year, according to the survey, conducted by GenomeWeb and investment bank William Blair. 

Canaccord and William Blair also increased their price targets on  Quidel's shares, following its acquisition of certain Alere assets and assays.

Mizuho and William Blair downgraded Bruker, following the resignation of CFO Charles Wagner, who was noted for his role in implementing a turnaround at the company.

In upgrading PacBio's shares to Outperform, the investment bank also took note of potential new revenues from its Roche deal and possibly a new platform launch next year.

The survey, conducted by GenomeWeb in conjunction with investment bank William Blair, found that users operate their NGS instruments at different capacities.

Cowen & Co. upgraded Fluidigm to an Outperform rating, while William Blair upgraded Hologic also to Outperform. 

Pages

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.